Execution of strategic plan results in continued growth, profitability and expansion of patient base

TALLAHASSEE, FL, May 28, 2019 – Trulieve Cannabis Corp. (“Trulieve”) (CSE: TRUL) today announced its financial results for the first quarter of 2019 ended March 31, 2019. Unless otherwise stated, all currency is expressed in U.S. dollars.

First Quarter 2019 Financial & Operational Highlights

  Subscribe to news from
Trulieve Cannabis

Be the first to know when breaking news are released.

  • Revenue grew 192% year over year, from $15.2 million in Q1 2018 to $44.5 million in Q1 2019
  • Adjusted EBITDA1,2 increased from $6.1 million in Q1 2018 to $19.0 million in Q1 2019
  • Successfully settled with the Florida Department of Health, increasing the potential number of Trulieve dispensaries to 14 above the state cap
  • First medical marijuana licensee to complete a sale of smokable flower following approval from Florida legislature
  • Establishment of four new dispensaries in Florida, bringing the total to 26 throughout the state
  • Received Minorities for Medical Marijuana’s inaugural 2018 Diversity and Inclusion Champion of the Year Award in the State of Florida

Recent Highlights & Developments

  • Increased number of U.S. states Trulieve operates in to four, following acquisition of Connecticut-based dispensary The Healing Corner
  • Received special permit to commence building our cultivation operations in Holyoke, Massachusetts
  • Signed agreement with Blue River™ Extracts & Terpenes to bring their products to the Florida market, recently launching their dry-sift rosin product
  • Filed final short form base shelf prospectus, valid for a 25-month period

“Our first quarter results reflect our ability to deliver on our strategic initiatives, translating into continued strong financial performance,” said Kim Rivers, CEO of Trulieve. “In addition to delivering on strong financial results we also achieved many significant milestones in the first quarter of the year. Growth continued in Florida with the opening of four new dispensaries, completing the first sale of smokable flower in Florida, and settling with the Florida Department of Health, allowing us an additional 14 stores above the state cap. We are very pleased with the progress we experienced in the beginning of 2019 and are continuing to see that same momentum carry into the second quarter.”

Financial Results

Results of operations

For the three months ended

For the three months ended
March 31

(Figures in millions and % change
based on these figures)

March 31


Dec 31





Total Revenue







Gross Margin2







Gross Margin %





Operating Expenses







Operating Expenses %





Adjusted EBITDA1,2







Reconciliation of Non-IFRS
Adjusted EBITDA

(Figures in millions and % change based
on these figures)

For the three months ended
March 31, 2019

Net Income (IFRS)


Add (Deduct) Impact of Net Effect
of Change in Fair Value of


Grow Cost for Unsold Inventory

Interest Expense, Net


Depreciation and Amortization


Depreciation included in Cost of Goods Sold


Provision for Income Taxes


Other Income, Net

Total Adjustments


Adjusted EBITDA1,2


The Management Discussion and Analysis for the period and the accompanying financial statements and notes are available under the Company’s profile on SEDAR at www.sedar.com  and on its website at https://www.trulieve.com/investors.

This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements. 


Moving through 2019, the Company will continue to focus on expanding its footprint in Florida as well as further establish operations in the additional states it has recently entered. Currently, Trulieve achieved its goal of reaching 30 stores by end of Q2 with 28 Trulieve dispensary locations operating in Florida, one in California, and one added through the Connecticut acquisition.

When considering the rapidly growing smokable flower market in the State of Florida, the Company dedicated a large portion of current crop capacity to address the pent-up demand for the product. As the medical cannabis patient base expands due to the access of medical flower, combined with existing patients shifting to the product for their medical relief, the Company is poised to be the market leader in the product space.

Financial Guidance

Given recent positive operational and market developments, the Company is updating its existing full year 2019 guidance and providing a long-term outlook.


(Guidance presented in
millions and % change)








$220 – $240

$380 – $400

Adjusted EBITDA1,2


$95 – $105

$140 – $160


EBITDA and Adjusted EBITDA are non-IFRS financial measures. While Trulieve believes that these measures are useful for the evaluation and assessment of its performance, they do not have any standard meaning prescribed by IFRS, are unlikely to be comparable to similar measures presented by other issuers and should not be considered as an alternative to comparable measures determined in accordance with IFRS.


Adjusted EBITDA and Gross margin do not include the net effect of changes in the fair value of biological assets.


Revenue is expected to grow 114% to 133% to a range of $220M to $240M. As previously disclosed, full year 2019 revenue growth guidance includes an expected increase in number of dispensaries in Florida as well as increased patient growth in the state due to the onboarding of smokable flower. Revenue and EBITDA from both California and Connecticut operations are also included. We expect adjusted EBITDA to be in the range of $95M to $105M reflecting our continued leverage of scale and financial discipline.


Guidance for 2020 incorporates our expansion into Massachusetts as well as continued growth in Florida, Connecticut, and California.  Based on these markets, current regulations, and foreseeable store growth, we estimate 2020 revenues in the range of $380M to $400M, generating $140M to $160M in adjusted EBITDA. 

Conference Call

The Company will host a conference call and live audio webcast on Wednesday, May 29, 2019 at 10:00 A.M. Eastern time, to discuss its first quarter 2019 financial results.

All interested parties can join the conference call by dialing 1-888-231-8191 or 1-647-427-7450, conference ID: 9573588. Please dial in 15 minutes prior to the call to secure a line. The conference call will be archived for replay until June 5, 2019 at midnight, ET. To access the archived conference call, please dial 1-855-859-2056 and enter the encore code 9573588.

A live audio webcast of the conference call will be available at: 

Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. An archived replay of the webcast will be available for 90 days by clicking the link above.

About Trulieve Cannabis Corp.

Trulieve is a vertically integrated “seed-to-sale” company and is the first and largest fully licensed medical cannabis company in the State of Florida. Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida, as well as directly to patients via home delivery. Trulieve also operates in California, Massachusetts and Connecticut. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the completion of the proposed acquisitions and the plans for the assets of the entities being acquired.  Words such as “expects”, “continue”, “will”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

SOURCE Trulieve Cannabis Corp.

Trulieve Reports Another Quarter of Record Revenue

For further information: Lynn Ricci, Director, Investor Relations, 1-850-270-5691, IR@trulieve.com